Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Trabectedin × Gynecologic × Clear all

Phase

Phase 3 5 Phase 2 5 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Ovarian Neoplasms 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 7 human papillomavirus vaccine, L1 type 16, 18 5 niraparib 4 Human Papillomavirus Recombinant Vaccine nonavalent 4 Vaccines 3 Saline Solution 3 Papillomavirus Vaccines 3 Carboplatin 3 pegylated granulocyte colony-stimulating factor 2 olaparib 2 liposomal doxorubicin 2 fluciclovine F-18 2 apatinib 2 Sevoflurane 2 Propofol 2 Paclitaxel 2 Medroxyprogesterone Acetate 2 Bevacizumab 2 pegfilgrastim 1 pazopanib 1 palbociclib 1 lenvatinib 1 ganirelix 1 gadofosveset trisodium 1 fosaprepitant 1 ferrous fumarate 1 epoetin beta 1 dostarlimab 1 cetrorelix 1 anlotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03164980 2025-03-20

COMPASS

North Eastern German Society of Gynaecological Oncology

Phase 4 Terminated

89 enrolled 20 charts

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡